From $0 to $12B in an instant. Here's why biopharma loves risky Alzheimer's studies
Anyone who is struggling to understand why biopharma companies are willing to sink billions into pivotal trials built around failed theories on how to treat Alzheimer’s need only check out SVB Leerink analyst Geoffrey Porges’ note on Biogen this morning for insight.
Porges had a chance to consult with a key opinion leader in the field who wasn’t involved in the aducanumab studies at Biogen but who is optimistic about the company’s chances of winning an approval for the drug. The analyst’s unnamed expert was bullish that the single positive study that showed a reduction in the rate of decline among patients — EMERGE — would be enough to win an approval as the first disease-modifying drug for the memory-wasting disease.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.